Which company produces Elacetrant?

Elacestrant is a new type of selective estrogen receptor degrader (SERD). It is currently mainly used to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, especially for patients who have received multiple lines of endocrine therapy and have ESR1 mutations. The drug blocks the dependence of tumor cells on estrogen signals by binding to estrogen receptors and inducing their degradation, thereby delaying or preventing the growth and spread of cancer cells. Compared with traditional SERD drugs such as Fulvestrant, the oral dosage form of elastrant brings higher compliance and also solves the problems of low bioavailability and inconvenience of use of injectable drugs, and has significant clinical advantages.

The research and development of elastran was initially completed by the American biopharmaceutical companyRadius Health, which focuses on the development of new drugs in the fields of endocrinology and oncology. Subsequently, the global commercialization rights of the drug were acquired and promoted by Italian pharmaceutical giant Menarini Group. Menarini is an international pharmaceutical company founded in 1886 and one of Europe's leading private pharmaceutical companies. It has a wide range of products and rich clinical experience in oncology, cardiovascular diseases, respiratory diseases and other fields. As a result, under his leadership, elastran completed key clinical trials and was approved by the U.S. FDA in early 2023 under the trade name Orserdu, becoming the world's first oral SERD drug approved for ESR1-mutated breast cancer.

At present, elastran has been marketed in many countries and regions such as the United States and the European Union, but it has not yet been officially approved in mainland China. If patients need to use it, they can obtain the drug through overseas medical channels and need to use it under the guidance of a doctor.

References:https://www.drugs.com/mtm/elacestrant.html